Multiple Sclerosis, Chronic Progressive
"Multiple Sclerosis, Chronic Progressive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
Descriptor ID |
D020528
|
MeSH Number(s) |
C10.114.375.500.200 C10.314.350.500.200 C20.111.258.250.500.200
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Chronic Progressive".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Chronic Progressive".
This graph shows the total number of publications written about "Multiple Sclerosis, Chronic Progressive" by people in this website by year, and whether "Multiple Sclerosis, Chronic Progressive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 13 | 0 | 13 |
2018 | 8 | 1 | 9 |
2019 | 5 | 1 | 6 |
2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis, Chronic Progressive" by people in Profiles.
-
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflamm. 2021 07; 8(5).
-
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021 02; 8(2):385-394.
-
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord. 2021 Feb; 48:102704.
-
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler. 2020 09; 26(10):1261-1264.
-
COVID-19 in MS: Initial observations from the Pacific Northwest. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
-
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. Mult Scler Relat Disord. 2020 08; 43:102224.
-
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020 Aug; 43:102195.
-
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum. Rev Neurol (Paris). 2020 06; 176(6):523-525.
-
One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients. Mult Scler Relat Disord. 2020 06; 41:102138.
-
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020 Jul; 42:102120.